Dissecting the role of the mitochondrial chaperone mortalin in Parkinson's disease: Functional impact of disease-related variants on mitochondrial homeostasis

Lena F. Burbulla, Carina Schelling, Hiroki Kato, Doron Rapaport, Dirk Woitalla, Carola Schiesling, Claudia Schulte, Manu Sharma, Thomas Illig, Peter Bauer, Stephan Jung, Alfred Nordheim, Ludger Schöls, Olaf Riess, Rejko Krüger

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

The mitochondrial chaperone mortalin has been linked to neurodegeneration in Parkinson's disease (PD) based on reduced protein levels in affected brain regions of PD patients and its interaction with the PDassociated protein DJ-1. Recently, two amino acid exchanges in the ATPase domain (R126W) and the substrate-binding domain (P509S) of mortalin were identified in Spanish PD patients. Here, we identified a separate and novel variant (A476T) in the substrate-binding domain of mortalin in German PD patients. To define a potential role as a susceptibility factor in PD, we characterized the functions of all three variants in different cellular models. In vitro import assays revealed normal targeting of all mortalin variants. In neuronal and non-neuronal human cell lines, the disease-associated variants caused a mitochondrial phenotype of increased reactive oxygen species and reduced mitochondrial membrane potential, which were exacerbated upon proteolytic stress. These functional impairments correspond with characteristic alterations of the mitochondrial network in cells overexpressing mutant mortalin compared with wild-type (wt), which were confirmed in fibroblasts from a carrier of the A476T variant. In line with a loss of function hypothesis, knockdown of mortalin in human cells caused impaired mitochondrial function that was rescued by wt mortalin, but not by the variants. Our genetic and functional studies of novel disease-associated variants in the mortalin gene define a loss of mortalin function, which causes impaired mitochondrial function and dynamics. Our results support the role of this mitochondrial chaperone in neurodegeneration and underscore the concept of impaired mitochondrial protein quality control in PD.

Original languageEnglish
Pages (from-to)4437-4452
Number of pages16
JournalHuman Molecular Genetics
Volume19
Issue number22
DOIs
Publication statusPublished - Nov 2010
Externally publishedYes

Fingerprint

Parkinson Disease
Homeostasis
Mitochondrial Dynamics
mortalin
Mitochondrial Membrane Potential
Mitochondrial Proteins
Quality Control
Adenosine Triphosphatases
Reactive Oxygen Species
Fibroblasts
Phenotype
Amino Acids
Cell Line
Brain
Genes
Proteins

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Dissecting the role of the mitochondrial chaperone mortalin in Parkinson's disease : Functional impact of disease-related variants on mitochondrial homeostasis. / Burbulla, Lena F.; Schelling, Carina; Kato, Hiroki; Rapaport, Doron; Woitalla, Dirk; Schiesling, Carola; Schulte, Claudia; Sharma, Manu; Illig, Thomas; Bauer, Peter; Jung, Stephan; Nordheim, Alfred; Schöls, Ludger; Riess, Olaf; Krüger, Rejko.

In: Human Molecular Genetics, Vol. 19, No. 22, 11.2010, p. 4437-4452.

Research output: Contribution to journalArticle

Burbulla, LF, Schelling, C, Kato, H, Rapaport, D, Woitalla, D, Schiesling, C, Schulte, C, Sharma, M, Illig, T, Bauer, P, Jung, S, Nordheim, A, Schöls, L, Riess, O & Krüger, R 2010, 'Dissecting the role of the mitochondrial chaperone mortalin in Parkinson's disease: Functional impact of disease-related variants on mitochondrial homeostasis', Human Molecular Genetics, vol. 19, no. 22, pp. 4437-4452. https://doi.org/10.1093/hmg/ddq370
Burbulla, Lena F. ; Schelling, Carina ; Kato, Hiroki ; Rapaport, Doron ; Woitalla, Dirk ; Schiesling, Carola ; Schulte, Claudia ; Sharma, Manu ; Illig, Thomas ; Bauer, Peter ; Jung, Stephan ; Nordheim, Alfred ; Schöls, Ludger ; Riess, Olaf ; Krüger, Rejko. / Dissecting the role of the mitochondrial chaperone mortalin in Parkinson's disease : Functional impact of disease-related variants on mitochondrial homeostasis. In: Human Molecular Genetics. 2010 ; Vol. 19, No. 22. pp. 4437-4452.
@article{51470c93d70743569e8d7b87f0bd0520,
title = "Dissecting the role of the mitochondrial chaperone mortalin in Parkinson's disease: Functional impact of disease-related variants on mitochondrial homeostasis",
abstract = "The mitochondrial chaperone mortalin has been linked to neurodegeneration in Parkinson's disease (PD) based on reduced protein levels in affected brain regions of PD patients and its interaction with the PDassociated protein DJ-1. Recently, two amino acid exchanges in the ATPase domain (R126W) and the substrate-binding domain (P509S) of mortalin were identified in Spanish PD patients. Here, we identified a separate and novel variant (A476T) in the substrate-binding domain of mortalin in German PD patients. To define a potential role as a susceptibility factor in PD, we characterized the functions of all three variants in different cellular models. In vitro import assays revealed normal targeting of all mortalin variants. In neuronal and non-neuronal human cell lines, the disease-associated variants caused a mitochondrial phenotype of increased reactive oxygen species and reduced mitochondrial membrane potential, which were exacerbated upon proteolytic stress. These functional impairments correspond with characteristic alterations of the mitochondrial network in cells overexpressing mutant mortalin compared with wild-type (wt), which were confirmed in fibroblasts from a carrier of the A476T variant. In line with a loss of function hypothesis, knockdown of mortalin in human cells caused impaired mitochondrial function that was rescued by wt mortalin, but not by the variants. Our genetic and functional studies of novel disease-associated variants in the mortalin gene define a loss of mortalin function, which causes impaired mitochondrial function and dynamics. Our results support the role of this mitochondrial chaperone in neurodegeneration and underscore the concept of impaired mitochondrial protein quality control in PD.",
author = "Burbulla, {Lena F.} and Carina Schelling and Hiroki Kato and Doron Rapaport and Dirk Woitalla and Carola Schiesling and Claudia Schulte and Manu Sharma and Thomas Illig and Peter Bauer and Stephan Jung and Alfred Nordheim and Ludger Sch{\"o}ls and Olaf Riess and Rejko Kr{\"u}ger",
year = "2010",
month = "11",
doi = "10.1093/hmg/ddq370",
language = "English",
volume = "19",
pages = "4437--4452",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "22",

}

TY - JOUR

T1 - Dissecting the role of the mitochondrial chaperone mortalin in Parkinson's disease

T2 - Functional impact of disease-related variants on mitochondrial homeostasis

AU - Burbulla, Lena F.

AU - Schelling, Carina

AU - Kato, Hiroki

AU - Rapaport, Doron

AU - Woitalla, Dirk

AU - Schiesling, Carola

AU - Schulte, Claudia

AU - Sharma, Manu

AU - Illig, Thomas

AU - Bauer, Peter

AU - Jung, Stephan

AU - Nordheim, Alfred

AU - Schöls, Ludger

AU - Riess, Olaf

AU - Krüger, Rejko

PY - 2010/11

Y1 - 2010/11

N2 - The mitochondrial chaperone mortalin has been linked to neurodegeneration in Parkinson's disease (PD) based on reduced protein levels in affected brain regions of PD patients and its interaction with the PDassociated protein DJ-1. Recently, two amino acid exchanges in the ATPase domain (R126W) and the substrate-binding domain (P509S) of mortalin were identified in Spanish PD patients. Here, we identified a separate and novel variant (A476T) in the substrate-binding domain of mortalin in German PD patients. To define a potential role as a susceptibility factor in PD, we characterized the functions of all three variants in different cellular models. In vitro import assays revealed normal targeting of all mortalin variants. In neuronal and non-neuronal human cell lines, the disease-associated variants caused a mitochondrial phenotype of increased reactive oxygen species and reduced mitochondrial membrane potential, which were exacerbated upon proteolytic stress. These functional impairments correspond with characteristic alterations of the mitochondrial network in cells overexpressing mutant mortalin compared with wild-type (wt), which were confirmed in fibroblasts from a carrier of the A476T variant. In line with a loss of function hypothesis, knockdown of mortalin in human cells caused impaired mitochondrial function that was rescued by wt mortalin, but not by the variants. Our genetic and functional studies of novel disease-associated variants in the mortalin gene define a loss of mortalin function, which causes impaired mitochondrial function and dynamics. Our results support the role of this mitochondrial chaperone in neurodegeneration and underscore the concept of impaired mitochondrial protein quality control in PD.

AB - The mitochondrial chaperone mortalin has been linked to neurodegeneration in Parkinson's disease (PD) based on reduced protein levels in affected brain regions of PD patients and its interaction with the PDassociated protein DJ-1. Recently, two amino acid exchanges in the ATPase domain (R126W) and the substrate-binding domain (P509S) of mortalin were identified in Spanish PD patients. Here, we identified a separate and novel variant (A476T) in the substrate-binding domain of mortalin in German PD patients. To define a potential role as a susceptibility factor in PD, we characterized the functions of all three variants in different cellular models. In vitro import assays revealed normal targeting of all mortalin variants. In neuronal and non-neuronal human cell lines, the disease-associated variants caused a mitochondrial phenotype of increased reactive oxygen species and reduced mitochondrial membrane potential, which were exacerbated upon proteolytic stress. These functional impairments correspond with characteristic alterations of the mitochondrial network in cells overexpressing mutant mortalin compared with wild-type (wt), which were confirmed in fibroblasts from a carrier of the A476T variant. In line with a loss of function hypothesis, knockdown of mortalin in human cells caused impaired mitochondrial function that was rescued by wt mortalin, but not by the variants. Our genetic and functional studies of novel disease-associated variants in the mortalin gene define a loss of mortalin function, which causes impaired mitochondrial function and dynamics. Our results support the role of this mitochondrial chaperone in neurodegeneration and underscore the concept of impaired mitochondrial protein quality control in PD.

UR - http://www.scopus.com/inward/record.url?scp=77958479016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958479016&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddq370

DO - 10.1093/hmg/ddq370

M3 - Article

C2 - 20817635

AN - SCOPUS:77958479016

VL - 19

SP - 4437

EP - 4452

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 22

ER -